YC Biotech has officially signed the “DNA Methylation Cancer Marker Testing Agreement” with multiple clinics within the New Banqiao Health Care Group, marking a significant step forward in the clinical adoption of breast cancer methylation testing. The agreement was formalized during a signing banquet, underscoring a shared commitment to advancing early cancer detection through cutting-edge medical technology.
This innovative testing method provides a more sensitive and specific approach to breast cancer detection while ensuring a more comfortable experience for patients undergoing screening. By integrating this technology into clinical practice, the collaboration aims to enhance diagnostic accuracy and improve early intervention strategies.
At the event, YC Biotech engaged in in-depth discussions with clinic representatives, exploring the practical applications and future potential of breast cancer methylation testing. The strong interest and valuable feedback from medical professionals will play a key role in optimizing the implementation and expansion of this technology.
As a major healthcare provider in northern Taiwan, New Banqiao Health Care Group continues to prioritize the adoption of advanced diagnostic tools to elevate the quality of its medical services. This partnership with YC Biotech further strengthens its efforts to enhance precision medicine and provide patients with more efficient and reliable screening options.
Looking ahead, YC Biotech remains committed to ongoing research and development, not only refining its breast cancer methylation testing technology but also exploring its potential applications in other cancers, including colorectal and pancreatic cancer. With a focus on innovation, the company continues to drive progress in precision medicine, working toward its mission of improving healthcare outcomes and enhancing quality of life.